Monthly Archives: January 2011

The February 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 17, Issue 1

Editorial

Applying design thinking to biotechnology PDF
Yali Friedman

Commentary

Building biotechnology by design: An entrepreneur’s perspective PDF
Arthur A Boni
Building biotechnology by design: Role of biotechnology in development PDF
Patrick Nef

Articles

Pricing biologics: Issues, strategic priorities and a conceptual model PDF
Sanjay K Rao
Revitalizing portfolio decision-making at Merck Serono S.A. – Geneva PDF
Vincent Aurentz, Bernhard Kirschbaum, Markus Thunecke
Global consensus – Need of the hour for genetically modified organisms (GMO) labeling PDF
Jagadeesan Premanandh
Beyond investment: Advancing the biotechnology sector in the countries of the Gulf Cooperation Council (GCC) PDF
Leonard Lerer, Brett Bowman

Case Study

Repurposing of the epidermal growth factor PDF
Ernesto L Mola, José A Buxadó, Luis Herrera
Biotechnology commercialization: A case study from Central and Eastern Europe PDF
Dana Ukropcova, Ernest Sturdik
The developments in the business models of biotechnology in the Central and Eastern European countries: The example of Estonia PDF
Margit Suurna

Legal and Regulatory Updates

EU Legal and Regulatory Update PDF
Gerry Kamstra

I will be teaching Biotechnology Management (TECH 566) again this spring at the National Institutes of Health Foundation for Advanced Education in the Sciences. The focus of this course is on learning the skills necessary to succeed in the biotechnology industry. Classes are comprised of a combination of lectures based on my textbook, Building Biotechnology, and guest lectures from local entrepreneurs, financiers, and biotechnology company management.

Classes start on January 25th, and are held on Tuesday evenings in the NIH Office of Technology Transfer offices. For more details, see TECH 566 in the FAES course catalog.

Drug Patent Expirations in January 2011

*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
VITRAVENE PRESERVATIVE FREE Novartis fomivirsen sodium 5,276,019 Jan 4, 2011
ELIGARD Tolmar Therap leuprolide acetate 5,278,201 Jan 11, 2011
ULTIVA Bioniche Teoranta remifentanil hydrochloride 5,019,583*PED Jan 12, 2011
XELODA Hoffmann La Roche capecitabine 4,966,891 Jan 13, 2011
DUETACT Takeda Global glimepiride; pioglitazone hydrochloride 4,687,777 Jan 17, 2011
ACTOS Takeda Pharms Na pioglitazone hydrochloride 4,687,777 Jan 17, 2011
ACTOPLUS MET Takeda Global metformin hydrochloride; pioglitazone hydrochloride 4,687,777 Jan 17, 2011
ACTOPLUS MET XR Takeda Global metformin hydrochloride; pioglitazone hydrochloride 4,687,777 Jan 17, 2011
PROTONIX IV Wyeth Pharms Inc pantoprazole sodium 4,758,579*PED Jan 19, 2011
PROTONIX Wyeth Pharms Inc pantoprazole sodium 4,758,579*PED Jan 19, 2011
EMEND Merck aprepitant 5,145,684 Jan 25, 2011
MEGACE ES Par Pharm megestrol acetate 5,145,684 Jan 25, 2011
TRICOR Abbott fenofibrate 5,145,684 Jan 25, 2011
VFEND Pfizer voriconazole 5,773,443 Jan 25, 2011
BAYCOL Bayer Pharms cerivastatin sodium 5,177,080 Jan 26, 2011

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com